Navigation Links
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Date:8/7/2008

nd tolerability of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in 48 HIV-positive patients who were naive to antiretroviral treatment. Nine out of 12 patients in each of four cohorts received RDEA806. The primary efficacy end point was the change from baseline in plasma viral load. Results from all four cohorts showed a median reduction in plasma viral load at nadir of 1.8 - 2.0 log copies/mL. There were no serious adverse events, premature discontinuations, clinically relevant ECGs changes or drug-related rash reported in any cohort. The incidence of CNS side effects was similar between drug and placebo. Gastrointestinal side effects were most common, but these effects were generally transient and mild.

The presentation is available on the conference website (http://www.aids2008.org) and on the Company website (http://www.ardeabio.com) under the title "Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients."

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, we believe that RDEA806 may have important competitive advantages compared to currently available NNRTIs. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... LEHIGH VALLEY, Pa. , July 28, 2014 /PRNewswire/ ... a reliable, uninterrupted supply of medical oxygen is vital ... company to technical innovations that not only improve the ... gas use. Air Products will highlight these systems—including systems ... systems that reduce oxygen loss—from August 4-5 at the ...
(Date:7/28/2014)... 28, 2014  Array BioPharma Inc. (Nasdaq:   ... fourth quarter and full year of fiscal ... discuss those results on Tuesday, August 12, ... Michael Carruthers , Chief Financial Officer ... 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2
... Reportlinker.com announces that a new market research ... The Outlook for Medical ... http://www.reportlinker.com/p0192649/The-Outlook-for-Medical-Devices-in-South-East-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care ... the Middle East is published by Espicom ...
... Belt Technologies, Inc., a medical device company focused ... providing precise robotic control for use initially in ... including neurosurgery, spinal and otolaryngology ("NET"), announced today ... partial knee replacements will be featured at the ...
Cached Medicine Technology:The Outlook for Medical Devices in South East Asia 2The Outlook for Medical Devices in South East Asia 3The Outlook for Medical Devices in South East Asia 4The Outlook for Medical Devices in South East Asia 5Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK 2
(Date:7/28/2014)... St. Jude Children’s Research Hospital ... of Defense Employer Support Freedom Award from the Employer Support ... Defense. The award is the highest honor given by the ... who serve in the National Guard and Reserve. , “We ... their contributions to the St. Jude mission and to our ...
(Date:7/28/2014)... possible by a test developed at University of Colorado ... of Pharmacy), AURORA, Colo (July 28, 2014) An influential ... Pharmacology Laboratory at the CU School of Pharmacy, helps ... Truvada (a combination of tenofovir/emtricitabine), which is taken once ... presented during the AIDS 2014 Conference and published in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... Lipase), Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, ... Forecasts to 2018” defines and segments the global ... the global value for industrial enzymes. It also ... industrial enzymes market with analysis of trends, opportunities, ...
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... Dennis Thompson HealthDay ... -- Babies born prematurely appear to have a slightly ... will carry into adulthood, Swedish researchers report. Doctors ... weeks, gestation have a raised risk of deep vein ... blood clotting in the veins, the researchers noted in ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3
... a team of researchers an expression pattern of certain ... in lunch cancer patients.// ,The analysis of these ... of diagnostic and prognostic tools for lung cancer. ... Ohio; the Jikei University School of Medicine, Tokyo, Japan; ...
... for the final hearing of India's biggest ever medical compensation ... in a woman's death eight years ago.// ,"I ... again be postponed by the machinations of my opponents," Ohio-based ... of the final hearing at the National Consumer Disputes Redressal ...
... Welfare has said that measures taken to check the ... sums in public health expenditure. // Preventive Health Initiatives ... to statistics, these spending are just $68 a year ... $77 million was expended on public health programs in ...
... rendered to Scotland children, could soon come to an end, ... by ministers. // Dental practices in Scotland yield a considerable ... of registered NHS patients. ,There exists a flaw ... extra payments, says the British Dental Association (BDA). This could ...
... Health Service has conducted a study and found that the rates ... , More parents are getting their children immunized with the ... below the Scottish Executive's target level of 95% by the age ... of immunization. The drop was due to the vaccines association with ...
... soon be launched for commercial use in Hungary following ... Minister, Ferenc Gyurcsany, made the announcement. ,Hungary ... year. Vaccine trials conducted on animal and human models ... claimed to confer protection against the H5N1 virus that ...
Cached Medicine News:Health News:Lung cancer molecular profile discovered by researchers. 2Health News:Stage Set For Final Hearing On India’s Biggest Ever Medical Compensation Clai 2Health News:Children In Scotland Denied Access To Dental Care 2